Access cutting-edge prostate cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Check if you qualify for this prostate cancer clinical trial in New York, NY
If you're searching for prostate cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.